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1. Introduction  
With the advancement of nanotechnology and the development of molecular medicine, 
molecular and imaging becomes one of the most popular researches in the latest medicine. 
Molecular imaging can be defined as the imaging of targeted molecules non-invasively and 
repetitively in living organisms and cellular imaging can be defined similarly as the imaging 
of cells or cellular process non-invasively and repetitively in living organisms. At present, 
the common imaging tools for clinical study include ultrasound, computed tomography 
(CT), and magnetic resonance imaging (MRI). However, MRI is superior to CT for its better 
in soft tissue contrast, more sensitive in pathology detection, and lack of ionization 
irradiation.  
In clinical practice, gadolinium-contained compound is the commonest contrast medium 
used in MRI study. Molecular imaging differs from traditional imaging in that contrast 
agents are typically used to help identify particular biomarkers or pathways with high 
sensitivity and selectivity (Achilefu, 2010). However, gadolinium (Gd) is not proper for the 
molecular imaging and cellular imaging due to its low relaxivity, that further decrease upon 
cellular internalization; not biocompatible and potential toxicity following cellular 
dechelation over time. Iron oxide (IO) nanoparticle contrast medium is another contrast 
medium used in clinical study. They provide the most significant signal change per unit of 
metal atom, especially on T2* MR imaging. Iron oxide nanoparticle are made of thousands 
of iron atoms in Fe3O4 or γ-Fe2O3 form so that they can increase the contrast-to-noise ratio 
and make its sensitivity superior to Gd contrast agent on MR examination. Their main 
component, oxidized iron, can be metabolized in liver and recycled as important component 
of red blood cells. Iron oxide nanoparticle have a relatively long circulation time and low 
toxicity (Bradbury and Hricak 2005; Funovics et al., 2004; Harisinghani et al., 2003; Jain et al., 
2005; Montet et al., 2006). Their surfaces coating may strategically contain chemical linkage 
of functional groups and ligands for multimodal imaging purpose (Rogers & Basu, 2005). 
They can be easily detected by light and electron microscopy. Iron oxide nanoparticle posses 
some novel properties not seen with the other macromolecules. They can be manipulated by 
conjugating both targeting ligands or peptide and therapeutic components such as 
photosensitizer to help in diagnosis and treatment. Iron oxide nanoparticles can be used to 
monitor cellular migration, molecular events, and signal pathway associated with different 
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pathological status. Owing to its magnetic character, iron oxide nanoparticle can be 
manipulated magnetically and altered their magnetic character according to size of core and 
the condition of the coating. In this assay, we are going to review the characteristic and 
types of magnetic nanoparticles (MNP), especially the IO nanoparticles, the mechanism of 
internalization of MNP into the cell, the impact to cellular and other behaviour of 
macrophage and stem cell after labelling with MNP, and the future of application of MNP in 
nanomedicine.  
2. Magnetic resonance imaging and magnetic nanoparticles 
When we put a body into a strong magnetic field and then apply an external radiofrequency 
(RF) for a period. The RF may causes disturbance of the thermal equilibrium in the body 
system. After the RF stopped, MR imaging detects the different signals due to the different 
proton relaxation times (T) of hydrogen atom of the tissue in different body part. This makes 
MR offers great contrast between different soft tissues in the body. There are two types of 
MR imaging mechanisms: T1-weighted and T2-weighted. 
T1, the ‘‘longitudinal’’ (spin-lattice) relaxation time is defined as the time required for a 
substance to regain the 63% of its original longitudinal magnetization after an RF pulse. It 
represents the correlation of frequency between molecular motions and the Larmor 
frequency. The frequencies of small molecule (e.g. water) and large molecule (e.g. protein) 
are significantly different from the Larmor frequency and thereby have long T1 and 
present as low signal intensity (dark) on T1-weighted images. The motion frequency of 
medium-sized molecule such as cholesterol close to those used for MR imaging, thereby it 
has a short T1 relaxation time and thus appear high signal intensity (bright) on T1-
weighted images. T1 relaxation time can be shortened from the interaction between the 
unpaired electrons in the paramagnetic iron such as Gd ions in contrast medium and the 
protons in water. This makes those pathology with pooling of Gd contrast agent appear 
bright on T1-weighted images.  
T2 is the ‘‘transverse’’ (spin-spin) relaxation time. Following a 90 degree RF pulse, the 
protons lose their coherence and transverse magnetization. The tissue inhomogeneity causes 
fluctuations of the magnetic field randomly, leading to variations in the precession 
frequency of different spins on x-y plane. Consequently, the net x-y magnetization is lost 
since the initial phase coherence is lost. This results in T2 relaxation. Thus T2 relaxation is a 
measure of how long the resonating protons of a substance can be changed from coherent to 
de-coherent and then back to coherent stage following 90 degree RF pulse in x-y plane. T2 
relaxation time is defined as the time needed for the transverse magnetization decreases to 
37% of its original magnitude after a 90 degree RF pulse. Generally, T2 relaxation is much 
less dependent on the magnetic field strength than T1 relaxation time. However, the 
magnetic field is not homogenous, and the process is depending on the exact location of the 
molecules in the magnet. In such circumstances, a special transverse relaxation time 
constant is defined as T2*, which is usually much smaller than T2 and highly sensitive to 
magnetic field strength. 
The MR contrast medium can be divided into positive and negative contrast media 
according to their characteristic appearance on T1- weighted or T2-weighted images.  
www.intechopen.com
 
Magnetic Nanoparticles: Its Effect on Cellular Behaviour and Potential Applications 
 
359 
Positive contrast media appear brighter on MR images owing to a reduction in T1 relaxation 
time. They include those containing Gd, manganese or iron ions. Negative contrast agents 
appear dark on MR imaging due to shortening T1, T2, and T2* relaxation times. Iron oxide is 
the most common negative contrast medium used clinically. 
As mentioned before, gadolinium agent is not suitable for molecular or cellular imaging. In 
the last 10 years, most research of molecular imaging using MRI is focused on the 
application of IO nanoparticle.  
Compared to larger particles of the same chemical composition, nanoparticles can pass some 
biological barriers such as capillaries. Human albumin, a circulatory macromolecule, is 
similar to nanoparticles with a diameter of 5-10 nm (Wiwanitkit, 2006). Enzymes and 
receptors are also ranged in the similar size (Rawat, 2006). A nanoparticle of such size can 
have in excess of 1500 potential sites for chemical modification (Debbage et al., 2008; Harris 
et al., 2003) without loss of biological functionality. It is 150 times more than an antibody 
has. The high capacity for nanoparticle modification has led to their use as amplifiers for in 
vivo imaging. Both the surface properties and size of nanoparticles are important for their 
interaction with biological systems and therefore for their distribution in the circulation.  
In considering the use in in vivo imaging, the ideal IO nanoparticles is with small size (5–150 
nm) (table 1), high mass magnetization value, and great surface functionality. If the 
diameter of the MNPs is larger than 200 nm, they are usually taken up by the liver, spleen, 
and reticuloendothelial system and resulting in decreased blood circulation times. If their 
diameters are less than 5 nm, they are rapidly removed through the kidney (Gupta & Gupta, 
2005). Different sizes of IO nanoparticles including SPIO (superparamagnetic IO, 60–150 
nm), USPIO (ultrasmall SPIO, 10–50 nm), and MION (monocrystalline IO, 5–10 nm) can lead 
to different magnetic properties and function differently in various applications (Choi et al., 
2006; Corot et al., 2006; de Vries et al., 2005; Thorek et al., 2006; Wang et al. 2001;).  
The magnetism of MNP and its effect on MR imaging can depend significantly on their 
morphology, crystal structure, size and uniformity. The crystal structure of SPIO 
nanoparticle has the general formula of Fe3+O3M2+O, where M2+represents a divalent metal 
ion (i.e., iron, manganese, nickel, cobalt or magnesium) (Kateb et al., 2011). The ferric iron 
(Fe3+) makes the complex magnetic (Daldrup-Link et al., 2003; Wang et al., 2001) and large, 
unpaired, thermodynamically independent spines (single domain particles) makes the 
complex superparamagnetic. Single domain particles or magnetic domains have a net 
magnetic dipole. External magnetic fields can cause the magnetic domain to re-orient. The 
signal intensity of these MNP is related to the size of the particle, its position, its 
concentration within a given voxel, data acquisition parameters, the magnetic field, and 
dosage of the SPIO (Wang et al., 2001). In order to achieve higher relaxivity, types of MNPs 
have also been designed and included those doped with alternative metals such as CoFe2O4, 
NiFe2O4, MnFe2O4, Gd2O3 and gold-coated cobalt nanoparticles (Bouchard, et al., 2009; 
Bridot et al., 2007; Lee et al., 2007). Magnetism in MNPs is highly sensitive to its size because 
it arises from the collective interaction of atomic magnetic dipoles. At a critical size, MNPs 
will change from a state that has multiple magnetic domains to only a single domain. Below 
this critical size, the thermal energy becomes comparable to what is needed for spins to flip, 
and the magnetic dipoles are in status of rapid randomization. Such MNPs do not have 
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permanent magnetic moments in the absence of an external field but can quickly respond to 
an external magnetic field and are referred to as superparamagnetic.  
 

















Dextran T10, T1 
15-30 9.9 65 




20 n.a. n.a. 
Table 1. Examples of available SPIO and USPIO agents. Modified from Corot et al., 2006. 
MION has a magnetically labeled cell probe MR imaging agent with size about 5-10nm. It 
has monocrystallinity and can be used for receptor-directed MR imaging. Its small size 
make MION can easily pass through capillary endothelium without changing its 
supermagnetism. It has been stated that it is possible to be detected by MR imaging at 
concentration as low as 1 ug Fe/g tissue. Though it is still in the experimental state, the 
preliminary targeted MR imaging with MION prove to be a powerful tool for cellular and 
molecular MR imaging in the future. 
Many different chemical methods can be used for synthesizing magnetic nanoparticles. The 
most commonly used are precipitation-based approaches, either by co-precipitation or 
reverse micelle synthesis (Nitin et al., 2004; Shen et al., 1993). MNP without any surface 
coating are not stable in aqueous media, readily aggregate, and precipitate. For in vivo 
applications via intravenous route, these particles aggregates in blood frequently and are 
recognized and phagocytosed by macrophages (Lee et al., 2006). Therefore, the surface of 
MNP should be coated with a variety of different moieties that can eliminate or minimize 
their aggregation under physiological conditions. Usually, two main approaches are used 
for coating MNP, including in situ coatings and post-synthesis coatings (Berry et al., 2004; 
Horak et al., 2007; Jodin et al., 2006). With in situ coating, the MNP are coated during the 
synthesis process. This coating approach involves a co-precipitation process in the presence 
of the polysaccharide dextran and a cross linked chemically to increase its stability. This 
particular coating approach has been very successful in producing dextran SPIOs which are 
biocompatible and water – soluble. Other coatings in this class include carboxydextran 
coating, starch-based coating, and dendrimer-based coatings. The post-synthesis coatings 
can be used for coating MNP with a variety of materials, including, monolayer ligands, 
polymers, combinations of polymers and biomolecules such as phospholipids and 
carbohydrates, and silica.  
Multiple MNP can also be encapsulated in liposomes to create magnetoliposomes (De 
Cuyper & Joniau, 1988). Polyethylene glycol (PEG)-modified, phospholipid micelles coating 
is favourable since this can results in satisfactory solubility and stability in aqueous 
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solutions, well biocompatibility, and also with prolonged blood circulation time when they 
are delivered intravenously. The PEG can be modified for bioconjugation of various 
moieties such as antibody, oligonucleotides, and peptides and may allow for molecular 
specific intracellular targeting of specific proteins and nucleic acid (Gupta & Gupta, 2005; 
Kohler et al., 2004; Kumagai et al., 2007; Lee et al., 2006, 2007a; Mikhaylova et al., 2004; Nitin 
et al., 2004; Veiseh et al., 2005). PEG-coated MNP has the disadvantage such as limited 
binding sites available for further ligand binding (Gupta & Gupta, 2005), and the coating 
thickness can significantly affect their relaxivity (Laconte et al., 2007). In addition to PEG 
coating, other materials such as antibiofouling poly(TMSMA-r-PEGMA) (Lee et al., 2006), 
hyaluronic acid layers (Kumar et al., 2007) and carboxylfunctionalized poly(amidoamine) 
dendrimers of generation 3 (Shi et al., 2007) have also been used to coat the surface of IO 
nanoparticles for either increasing circulation time in the blood or delivering peptides at 
high efficiency.  
3. Impact of magnetic nanoparticles in immunologic cell 
For most of the clinical imaging application on magnetic nanoparticles, the delivery route is 
intravenous injection. The human immune system, mostly reticuloendothelial system, 
recognizes these magnetic nanoparticles and ingests them. The size and surface charge of 
the magnetic nanoparticles determine which kind of cells that interact with magnetic 
nanoparticles (Moghimi & Bonnemain 1999) For particles larger than 20 nm, macrophage 
and Kuppfer cell is the corresponding cells that deal with MNP (Moghimi & Hunter 2001, 
2005). If the MNPs are less than 20 nm, these MNPs have greater opportunity to reside in 
lymph nodes, after they extravasate into interstitial spaces (Moghimi & Bonnemain 1999). 
Currently clinical approved iron oxide nanoparticles for MR images ranged mostly from 50-
100 nm, in which macrophages play important roles in ingestion of these MNPs. 
Macrophages are cells that prevent invading bacteria, viruses by phagocytosis of these 
microbes. It initiates inflammatory change by secreting cytokines such as tumor necrosis 
factor-alpha and interleukin 2-beta which recruits more circulating cells for repairing 
damaged tissue. Recent studies reveal macrophages also play important roles in tumor 
invasion. Consequently, alteration of macrophage behaviour has potential influence on 
human immunity, inflammatory process and cancer invasion. Understanding of impacts of 
macrophages toward ingested magnetic nanoparticles is herein clinically important.  
Two different MNPs are now under clinical use. Ferucarbotran is composed of both Fe3O4 
(magnetite) and g-Fe2O3 (maghemite) and coated with carboxydextran that is negatively 
charged. Ferumoxides is also composed of iron oxide that coated with dextran. Protamine 
sulfate is usually added in cell culture for more efficient ferumoxides labelling (Arbab et al., 
2006).  
Studies on clinically used MNPs, ferucarbotran, toward murine macrophage cell line 
revealed MNPs ingestion stimulates TNF-alpha and IL-2 Beta secretion. The migratory 
ability of MNPs laden macrophage increased but the phagocytotic activity of macrophages 
decreased (Hsiao et al., 2008) However, these findings are based on 100 ug Fe/mL MNP 
concentration that is 11 times higher than plasma concentration (Metz et al., 2004). Similar 
findings could be observed on murine peritoneal macrophage cultured with 100 ug Fe/mL 
MNPs. The secretion of TNF-alpha, IL-2 Beta and Nitric oxide, a bactericidal chemical, are 
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all increased in conjunction with the promotion of macrophage migration ability (Yeh et al., 
2010).  
Long term exposure to MNPs has significant influence on macrophages. Research on human 
macrophages treated with ferucarbotran show increased apoptosis after 120 hours of 
incubation even at the concentration of 1 ug Fe/mL. Human macrophage also shows 
apoptotic change when facing smaller MNPs, supravist, a smaller particle of 20.8 nm in 
diameter, for 120 hours at the concentration of 0.1 ug Fe/mL (Lunov et al., 2010a). The 
apoptotic event is inducted by N-terminal kinase (JNK) pathway that is activated by reactive 
oxygen species (Lunov et al., 2010a; 2010b). There is evidence that elevated TNF-alpha 
induce human macrophage apoptosis after these macrophages expose to ferucarbotran for 
3- 5 days. However, there is no evidence that support ferucarbotran stimulate TNF-alpha 
secretion on human macrophage. All of studies performed above are in vitro experiments 
that intravenous injection of MNPs and collecting of circulating macrophage are still 
pending. Moreover, under intravenous injection condition, all of clinical MNPs are 
eliminated by reticuloendothelial system within 30 minutes in which no toxic event are 
observed.  
Human monocyte cell line, THP-1, is a precursor of macrophage and it has been evaluated 
for its interaction with ferumoxides. The ferumoxides has been mixed with 1mg/mL of 
protamine sulfate for higher labeling efficiency. Under incubation concentration of 4.5 ug 
Fe/mL of ferumoxides-protamine complex for 2 hours, there is no significant TNF-alpha 
secretion level change upon lipopolysaccharide stimulation (Janic et al., 2008). The CD-54 
and CD-83 is not upregulated in response to lipopolysaccharide.  
Lymphocytes are important immune cells that regulate both cellular and humoral immunity 
against invading organism and cancer cells. Although lymphocytes are not easily labeled 
with MNPs, it is still possible by modifying surface of MNPs with tat peptide, a HIV 
membrane translocating peptide that is specific to CD4+ lymphocytes (Garden et al., 2006). 
The synthesized Tat linked MNPs are 31.3± 8.5nm which is slightly larger than original 
MNPs that is 25.7± 6.1 nm. Under TEM, these particles located at both cytoplasm and 
nucleus, which is different from other MNPs that only located at lysosomes. There is neither 
proliferation ability nor IL-2 secretion capability change of CD4+ CD25+ lymphocytes after 
labelling with tat-linked MNPs (Garden et al., 2006). Dendritic cells are antigen presenting 
cells that express antigens to other immune cells, mostly lymphocytes, to continue immune 
response. Labelling of dendritic cells allows monitoring migration of these cells in vivo 
(Tavaré et al., 2011; Noh et al., 2011) The mouse dendritic cells were labelled with endorem, 
a clinically proved MNPs in Europe with corresponding product named ferumoxide in 
USA. There is no drastic effect of labelled dendritic cells such as T lymphocyte proliferation, 
in vivo growth rate of lymph nodes after labelled or unlabeled dendritic cells labelling. 
Under B16 melanoma lung metastatic model, both labelled and unlabeled dendritic cells 
show protective effect upon pulmonary metastasis (Tavaré et al., 2011). 
In conclusion, the effects of MNPs toward immune cells are diverse, the cell type, particle 
size, charge and labelling amount all contribute to cell behaviour change. Although some 
reports show immunological response change after MNPs labelling, most of the MNPs 
exceeds the daily clinical practice. However, systemically analysis of MNPs and immune 
cells interaction is important and this study may have potential impact on immune therapy.  
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4. Impact of magnetic nanoparticles in stem cell 
Stem cells play promising roles in tissue regeneration and engineering. They could be used 
for tissue transplantation and it is now understand that stem cells also interact with cancer 
cells. Some of the stem cell promotes the growth of cancer cells whereas some animal model 
shows stem cell suppresses the tumor growth.  
There are different types of stem cells. Embryonic stem cells are pluripotent, which means 
the cells could differentiate into almost all cells. However, the ethics concern and current 
stem cell technology progress makes it less interesting for cell labelling. Mesenchymal stem 
cells are multi-potent cells that could differentiate into different kinds of cells of medical 
interest such as bone tissue and cartilage.  
Bone marrow derived mesenchymal stem cells are capable of differentiating into many 
tissue that is essential for tissue repair. However, when these cells delivered into damaged 
tissue, it is hard to differentiate where these cells are. Labelling cells with MNPs are then 
important to monitor the location, migration in vivo. It has been proved that MNPs labelled 
mesenchymal stem cells can be visualized for implantation into damaged cardiac tissue in 
porcine model (Kraitchman et al., 2002). In the study, ferumoxides incorporated with poly-
L-lysine were incubated with swine mesenchymal stem cells and injected into 
myocardiocytes under X-ray guidance. Post-mortem histology shows injected cells resides 
in designated myocardial tissue. The labelled mesenchymal stem cells are also applied for 
monitoring the repair of lipopolysaccarides induced damaged brain tissue in rat model by 
using MNPs-tat peptide conjugate. The result shows cell migratory behaviour into the 
damaged brain (Jackson et al., 2010). For understanding of interaction between 
mesenchymal stem cells and tumor, labelled mesenchymal stem cells is also monitored for 
its interaction with glioma in mouse model by using ferucarbontran in conjunction with 
protamine sulfate and proved that mesenchymal stem cells reduce glioma growth and 
mesenchymal stem cells is capable of migration into glioma tissue (Chien et al., 2010). 
The mechanism of MNPs uptake by different kinds of stem cells are not fully investigated 
but recent study shows endocytosis by clathrin receptor is one of the mechanisms (Huang et 
al., 2005; Lu et al., 2007). These study shows inhibitor of clathrin receptor, phenylarsine 
oxide, can block the ingestion of mesoporous iron oxide nanoparticles into human 
mesenchymal stem cells. Macropinocytosis also play significant role once if protamine 
sulfate is used. It is also proved that tat peptide linked MNPs enter cell by macropinocytosis 
(Arbab et al., 2006). 
Most of stem cell labelling for MR imaging is based on T2 weighted contrast. However, 
some efforts aiming on T1 contrast agent such as gadolinium based chelates conjugating into 
mesoporous silica nanoparticles has been proved for its imaging capability in animals 
injected with human mesenchymal stem cells. The viability and differentiating capacity of 
these mesenchymal stem cells are preserved (Hsiao et al., 2008; Tsai et al., 2008). The 
mesoporous nanoparticles has also been labelled with fluorescent dyes that monitoring the 
cells with fluorescent imaging modality is also possible.  
In addition to cell viability, labelled mesenchymal stem cells has been verified for its 
mitochondrial potential and reactive oxygen species, both of which represents intracellular 
stress. Neither mitochondrial potential nor reactive oxygen species change under 
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ferucarbotran incubation at the concentration of 100 ug Fe/mL for 24 hours (Hsiao et al., 
2007). Long term incubation up to 72 hours has also been investigated and shows no adverse 
effect upon mesenchymal stem cells (Yang et al., 2011). Similar results are found on 
ferumoxide-polylysine and ferumoxides-protamine sulfate complex toward mesenchymal 
stem cells (Arbab et al., 2003; Pawelczyk et al., 2006).  
Stem cells are valuable for its differentiation capacity. Concerns for preserving its 
differentiating capacity are essential. For clinical used MNPs such as ferucarbotran for 
directly labelling, it has been showed that labelled mesenchymal stem cells is still capable of 
differentiating to adipose tissue, and bone tissue at the labelling period of 24 hours (Hsiao et 
al., 2007). The long term effect has also been evaluated for its cartilage differentiation 
capacity (Yang et al., 2011). The activity of chondrogenesis of ferucarbontran labelled 
mesenchymal stem cells decreased as iron content increases (Hinning et al., 2009). Similar 
finding upon osteogenesis is also found. Dose dependent osteogenesis inhibition is observed 
on human mesenchymal stem cells (Chen et al., 2010). The labelling dose is consequently 
very important.  
Labelling of mesenchymal stem cells with ferumoxides in conjunction with transfection 
agent is also popular. The differentiation capacity has also been studied. The adipogenesis 
and osteogenesis capacity is preserved but there is debate upon chondrogenesis (Kostura et 
al., 2004; Arbab et al., 2005). The model of ferumoxides-polylysine shows inhibition of 
chondrogenesis whereas ferumoxide-protamine sulfate shows no inhibitory effect. Although 
there is no study comparing these two labelling method, the ferumoxide-protamine sulfate 
and ferumoxide-polylysine complex, labelling mesenchymal stem cells with ferumoxide-
protamine sulfate might be better for further investigation. Besides, labelling dose of MNPs 
should be suitable for preserving imaging capability and differentiating capacity.  
In conclusion, labelling of stem cells for imaging is medically important that could be used 
for cell trafficking and potentially tumor inhibition. Although imaging capability of these 
labelled mesenchymal stem cells is concerned, the differentiation capacity of these cells 
should be preserved. Meanwhile, no satisfactory methods or consensus about labelling stem 
cell with MNP established though direct labelling using ferucarbotran or labelling 
ferumoxides with protamine sulfate are popular. Efforts on designing novel MNPs for cell 
labelling is still demanding.  
5. Bifunctional, multi-functional, and theragnostic magnetic nanoparticles 
Nanoparticles have advantages for their multi-conjugating capability that makes it possible 
to exhibit imaging and therapeutic character in one particle. The capability of imaging is 
mostly rely on the core that is magnetic. Either the shell or the core itself exhibit therapeutic 
effect. The therapeutic effects include gene delivery, hyperthermia, chemotherapy and 
photodynamic therapy. The benefits of theragnostic design are based on the following 
advantages. First, the magnetic core plays both imaging and magnetic guidance character. 
Targeting to specific organ or tissue is theoretically possible once if a guiding magnetic is 
applied. Secondly, the location where MNPs resides and acts as therapeutic agent can be 
visualized. Unlike most drugs that are small molecules, MNPs has different, specific organ 
and cell distribution that makes it possible for different treatment strategy. Lastly, MNPs 
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can traverse vasculature barrier and go into intercellular space or even cell surface once if 
recognizing molecules has been conjugated at the MNPs surface.  
Hyperthermia with MNPs is based on the fact that tumor cells are more liable toward 
temperature change. It have been investigated that temperature between 41°C and 42°C can 
induce tumor cell death by destruction of cell membrane (Sellins & Cohen, 1991). The 
enzymatic system is also influenced. The hyperthermia is achieved by alternating current 
magnetic field system around the frequency of 100 KHz at the magnetic field intensity in 
30.6 kA/m (Silva et al., 2011). Limited clinical trial was done and showed controversial 
effect (Maier-Hauff et al., 2007; 2011). In one study, 66 patients of glioblastoma, a high grade 
brain tumor, were enrolled and MNPs were injected into tumor of these patient. 
Hyperthermia associated with radiotherapy was done and there is statistical difference 
between hyperthermia group and traditional radiotherapy group. The survival after first 
diagnosis is 8.6 months longer in hyperthermia group compared with conventional 
treatment group. In addition, the adverse effect of hyperthermia is not significant according 
to the observation of the study (Maier-Hauff et al., 2011).  
Photodynamic therapy is one of the cancer treatment methods that have also been used for 
theragnostic purpose. The mechanism of photodynamic therapy is based on synthesis of 
singlet oxygen at the expense of photon activation of photosensitizer. The produced singlet 
oxygen is capable of destruct adjacent cells by oxidation. Some of the photosensitizers are 
clinically available. Efforts trying to conjugate MNPs with photosensitizers have potential 
benefits such as understanding the location of drugs accumulation and MNPs can also be 
guided by magnetic fields. The model of multi-functional MNPs has been proved possible in 
vitro. Hela cells can be imaged and killed by iridium complexes conjugated iron oxide 
nanoparticles (Lai et al., 2008). The iridium complexes have been also conjugated to MnO 
based mesoporous silicate nanoparticles that exhibit T1 weighted contrast enhancement. The 
photodynamic therapy effect is proved efficacious at in vitro HeLa cell model (Peng et al., 
2011).  
Gene therapy is at the edge of new strategy for cancer therapy. MNPs is capable of serving 
gene delivery carrier and also used for magnetic guidance. Studies focused on cancer related 
gene such as E1A has been successfully delivered into HeLa cells after E1A gene 
incoporated with iron oxide nanoparticles. Intratumoral injection of the plasmid-MNPs 
complex results in tumor size reduction compared with control group, whereas only 
radiation therapy was done (Shen et al., 2010).  
In conclusion, multifunctional MNPs are at the initial stage of development. The benefits of 
biodistribution and magnetic character make theragnostic strategy different from other 
treatment. However, more efforts upon toxicity and therapeutic range should be done 
before it has been used widely in the clinical medical fields.  
6. Future 
Cellular Imaging can be an application of MNP as cellular marker for imaging of 
macrophage activity and as cellular marker for imaging of cell migration and cell trafficking. 
With the advancement of modern molecule design, we can also have the capability of design 
a MNP with the role of both diagnostic and treatment.  
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A major limitation of IO MNP is the loss of signal on T2-weighted MRI and creating ‘black 
holes’ on images; that (1) prevent direct anatomical MR evaluation of the tissue in question 
(requiring comparison of pre- and post-contrast images), and (2) make it difficult to 
discriminate between targeted cells and image artefacts (i.e. as caused by susceptibility 
artifacts or imperfect pulse sequences).One such approach could be the use of a ‘white 
marker’ MR T1-weighted sequence, that creates positive MNP contrast. For cellular imaging, 
as labelling is not permanent and self-replicable like reporter genes, with dilution of label 
upon cell division, iron oxide detection may rapidly become impossible. Finally, careful iron 
oxide titration and cellular differentiation studies need to be performed. Short- and long-
term toxicity studies are warranted. It needs a comprehensive study on the fate of the 
particles in vivo following biodegradation; quantify the number of iron oxide labelled 
molecules or cells per voxel and to increase the specificity of detection of iron oxides.  
Perhaps the least studied limitation is the potential acute and chronic systemic toxicity of the 
particles themselves. Toxicity can result from the MNP themselves or the individual 
components of the MNP that can be released during degradation in vivo. Nanomaterials 
may influence a living organism through different biological pathways (Nel et al., 2006). 
From previous limited report IO MNP and gold colloids seem to be less of a concern in 
terms of toxicity and IO can be cleared from the body via various routes with minimal 
toxicity (Briley-Saebo et al., 2004; Corot et al., 2006; Jain et al., 2008). Different types of 
nanoparticles have been shown to be cytotoxic to human cells (Lewinski et al., 2008), induce 
oxidative stress (Long et al., 2006), or elicit an immune response (Dobrovolskaia et al., 2007). 
After administration, nanoparticles must traverse a complex and often hostile environments 
that have evolved to seek out and exclude foreign material (Minchin et al., 1999). The first 
few steps of this dangerous journey include the interacting with plasma proteins and 
accumulating in macrophages or the reticuloendothelial system of the liver, spleen, or 
lymph nodes. The types of proteins that absorb to the surface are affected by size, shape, 
and surface characteristics. Importantly, there is now strong evidence that the proteins that 
surround the nanoparticles play a critical role in determining their fate in vivo (Kreuter et 
al., 2002; Owens et al.; 2006, Lynch et al., 2006). Dextran is clinically approved for modifying 
IO MNP but liver accumulation is still evident. Silica nanoparticles have been evaluated for 
potential hepatoxicity because of their propensity to be taken up by the liver (Nishimori et 
al., 2009).Whereas large particles (>300nm) showed little adverse effects, particles less than 
100 nm induced acute liver damage and cytokine release.  
7. Conclusion 
The nanotechnology offer great opportunities for molecular imaging and future medicine. 
However, they are difficulty in designing and administration. The possible acute or chronic 
toxicity associated with the nanoparticle is still under investigated. The implementation of 
nanotechnology in medicine will depend on more understand and depth knowledge about 
them.  
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